Severity distribution and treatment of chronic obstructive pulmonary disease in China: baseline results of an observational study

Background Chronic obstructive pulmonary disease (COPD) receives low awareness and is undertreated in China. Understanding the burden and treatment of COPD across the nation is important for improving quality of care for this disease. This study aims to reveal the current situation of COPD severity distribution and management across China. Methods Baseline data from REALizing and Improving Management of Stable COPD in China, a multicentre, prospective, longitudinal, observational study, were analysed. Patients diagnosed with COPD as per Global Initiative for Chronic Obstructive Lung Disease 2016 (GOLD 2016) criteria were enrolled from 50 randomly selected hospitals (tertiary, 25; secondary, 25) across six geographical regions. Data were collected in routine clinical settings. Results Between 30 June 2017 and 29 January 2019, 5013 patients were enrolled and 4978 included in the full analysis set. Of these, 2459 (49.4%) reported ≥ 1 exacerbation within 12 months prior to study enrolment, with a mean annual rate of 0.9/patient, including 0.2/patient and 0.5/patient leading to emergency room visits and hospitalisation, respectively. Spirometry graded 458 (10.1%), 1886 (41.7%), 1558 (34.5%), and 616 (13.6%) were GOLD stage I–IV, and 536 (11.4%), 1034 (22.0%), 563 (12.0%), and 2566 (54.6%) were classified as GOLD 2016 Group A–D, respectively, without evident regional variations. Inhaled corticosteroids plus long-acting $ beta_{2} $-agonist (ICS/LABA, 1316 [26.4%]), ICS/LABA plus long-acting muscarinic antagonist (ICS/LABA + LAMA, 871 [17.5%]), and LAMA (754 [15.1%]) were prescribed at high rates across all groups and regions. Medications not recommended by GOLD were commonly prescribed (TCM, 578 [11.6%]; others, 951 [19.1%]), and 681 (13.7%) were not given ICS or long-acting bronchodilators. Conclusions Disease burden among Chinese COPD outpatients is high. Improved guideline adherence for COPD treatment is needed. Trial registration ClinicalTrials.gov identifier, NCT03131362..

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:23

Enthalten in:

Respiratory research - 23(2022), 1 vom: 29. Apr.

Sprache:

Englisch

Beteiligte Personen:

Yang, Ting [VerfasserIn]
Cai, Baiqiang [VerfasserIn]
Cao, Bin [VerfasserIn]
Kang, Jian [VerfasserIn]
Wen, Fuqiang [VerfasserIn]
Chen, Yahong [VerfasserIn]
Jian, Wenhua [VerfasserIn]
Shang, Hongyan [VerfasserIn]
Wang, Chen [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

COPD management
COPD severity
China
Chronic obstructive pulmonary disease (COPD)
Disease burden
Maintenance therapy
Observational study
Outpatients

Anmerkungen:

© The Author(s) 2022. corrected publication 2022

doi:

10.1186/s12931-022-02021-w

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC2130322840

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?